Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Her-2 PDF full book. Access full book title Her-2 by Robert Bazell. Download full books in PDF and EPUB format.
Author: Robert Bazell Publisher: Random House ISBN: 0307764982 Category : Health & Fitness Languages : en Pages : 241
Book Description
Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free. Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers. Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a "compassionate use" program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science.
Author: Robert Bazell Publisher: Random House ISBN: 0307764982 Category : Health & Fitness Languages : en Pages : 241
Book Description
Two years after she underwent a mastectomy and chemotherapy, Barbara Bradfield's aggressive breast cancer had recurred and spread to her lungs. The outlook was grim. Then she took part in Genentech's clinical trials for a new drug. Five years later she remains cancer-free. Her-2 is the biography of Herceptin, the drug that provoked dramatic responses in Barbara Bradfield and other women in the trials and that offers promise for hundreds of thousands of breast cancer patients. Unlike chemotherapy or radiation, Herceptin has no disabling side effects. It works by inactivating Her-2/neu--a protein that makes cancer cells grow especially quickly-- produced by a gene found in 25 to 30 percent of all breast tumors. Herceptin caused some patients' cancers to disappear completely; in others, it slowed the progression of the disease and gave the women months or years they wouldn't otherwise have had. Herceptin is the first treatment targeted at a gene defect that gives rise to cancer. It marks the beginning of a new era of treatment for all kinds of cancers. Robert Bazell presents a riveting account of how Herceptin was born. Her-2 is a story of dramatic discoveries and strong personalities, showing the combination of scientific investigation, money, politics, ego, corporate decisions, patient activism, and luck involved in moving this groundbreaking drug from the lab to a patient's bedside. Bazell's deft portraits introduce us to the remarkable people instrumental in Herceptin's history, including Dr. Dennis Slamon, the driven UCLA oncologist who played the primary role in developing the treatment; Lily Tartikoff, wife of television executive Brandon Tartikoff, who tapped into Hollywood money and glamour to help fund Slamon's research; and Marti Nelson, who inspired the activists who lobbied for a "compassionate use" program that would allow women outside the clinical trials to have access to the limited supplies of Herceptin prior to FDA approval of the drug. And throughout there are the stories of the heroic women with advanced breast cancer who volunteered for the trials, risking what time they had left on an unproven treatment. Meticulously researched, written with clarity and compassion, Her-2 is masterly reporting on cutting-edge science.
Author: David Khayat Publisher: S Karger Ag ISBN: 9783805573276 Category : Medical Languages : en Pages : 91
Book Description
The humanised monoclonal antibody Herceptin® targets human epidermal growth factor receptor-2 (HER2) positive cells, i.e. cells in which HER2 is overexpressed, a feature associated with many tumour characteristics. Approximately 20-30% of breast cancers are HER2 positive and are known to be particularly aggressive. Thus, HER2-positive clinical trials of Herceptin® have clearly demonstrated that it provides significant clinical benefit in HER2-positive metastatic dis-ease, most importantly increased survival when administered first line in combination with chemotherapy. The articles in this supplement review our knowledge of the activity of HER2 and how to test for HER2 status, and describe the clinical trials of Herceptin® that have been performed today. In conclusion, future research with this novel agent is likely to change the management of cancer patients and further improve the efficacy of therapy.
Author: Connie Henke Yarbro Publisher: Jones & Bartlett Learning ISBN: 9780763747206 Category : Medical Languages : en Pages : 1928
Book Description
Rapid changes in oncology necessitate a comprehensive, up-to-date reference for oncology nurses. For seventeen years, best-selling Cancer Nursing: Principles and Practice has filled this need, supplying oncology nurses with cutting-edge, current information. Now, in its Sixth Edition, Cancer Nursing reflects the constantly shifting progress in the science of oncology, as well as emerging new therapies, new treatment modalities, the latest results from clinical trials, updates on new chemotherapeutic agents and targeted therapies, and new perspectives on supportive care.
Author: Melvyn Little Publisher: Springer Nature ISBN: 3030725995 Category : Medical Languages : en Pages : 153
Book Description
This book presents a compact overview of the history, evolution and fascinating novel applications of antibodies for the treatment of cancer, leading the reader step by step to the latest advances. Interesting anecdotes, together with self-explanatory and clearly structured figures with a humorous touch, facilitate the reader’s understanding of this complex topic. Clinical cases round out the book, making it a valuable aid for professionals in their everyday practice. The growing importance of the topics covered here was highlighted by the joint award of the 2018 Nobel Prize in Chemistry to Frances H. Arnold (directed evolution of enzymes), George P. Smith (phage display of peptides) and Sir Gregory P. Winter (phage display of antibodies). Furthermore, the 2018 Nobel Prize in Physiology or Medicine was awarded to James P. Allison and Tasuku Honjo for their discovery of cancer therapy by inhibition of negative immune regulation. Many of the antibodies that are now being brought to market target precisely these immune checkpoint modulators. The book addresses a broad readership, ranging from professionals and experts in the field to residents and medical students.
Author: Laurent Degos Publisher: CRC Press ISBN: 1841841455 Category : Medical Languages : en Pages : 1492
Book Description
The Second Edition of this successful title has been fully revised and updated and now includes expanded sections on normal and malignant haematopoiesis, offering a thorough review of the molecular and cellular processes involved in malignancy, developments in diagnostic techniques and treatment, concluding with discussion of treatment of individual diseases, late effects of therapy and supportive care. Short Contents
Author: Stan B. Kaye` Publisher: CRC Press ISBN: 9781853178252 Category : Medical Languages : en Pages : 804
Book Description
Effective care of the cancer patient increasingly involves systemic treatment, and as the range of available therapeutic agents continues to expand, the medical oncologist must be fully aware of the combinations. This new edition provides a practical overview of the many treatment choices, and has been fully updated, including discussion of new classification systems, anticancer agents and treatment protocols.
Author: Kristin Ciriello Pothier Publisher: John Wiley & Sons ISBN: 1118792114 Category : Medical Languages : en Pages : 278
Book Description
The author uses decades of experience and interviews with experts in precision medicine to explain past, present, and future of precision medicine. She reviews the full continuum of personalizing precision medicine, including diagnostics, therapeutics, big data, supportive care, regulation, and reimbursement and innovation in precision medicine worldwide. • Combines a unique cross section of history, current technologies, and future directions for how precision medicine has and will affect people worldwide • Reviews precision medicine around the world, including the US, China, Japan, the Middle East, India, Europe, and Latin America • Discusses a number of diseases areas – cancer, cardiovascular, neurodegenerative, infectious disease, pain, immunology, rare diseases • Includes information and quotes from over 100 interviews with key industry experts in biotech, pharma, informatics, diagnostics, health providers, advocacy groups, and more. • Includes stories illustrating current issues and future promises in precision medicine for a human touch
Author: Sara Hurvitz Publisher: Elsevier Health Sciences ISBN: 0323581234 Category : Medical Languages : en Pages : 264
Book Description
Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today’s available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists.
Author: Jeffrey Medin Publisher: Springer Science & Business Media ISBN: 1607619806 Category : Medical Languages : en Pages : 447
Book Description
Immunotherapy is now recognized as an essential component of treatment for a wide variety of cancers. It is an interdisciplinary field that is critically dependent upon an improved understanding of a vast network of cross-regulatory cellular populations and a diversity of molecular effectors; it is a leading example of translational medicine with a favorable concept-to-clinical-trial timeframe of just a few years. There are many established immunotherapies already in existence, but there are exciting new cancer immunotherapies just on the horizon, which are likely to be more potent, less toxic and more cost effective than many therapies currently in use. Experimental and Applied Immunotherapy is a state-of-the-art text offering a roadmap leading to the creation of these future cancer-fighting immunotherapies. It includes essays by leading researchers that cover a wide variety of topics including T cell and non-T cell therapy, monoclonal antibody therapy, dendritic cell-based cancer vaccines, mesenchymal stromal cells, negative regulators in cancer immunology and immunotherapy, non-cellular aspects of cancer immunotherapy, the combining of cancer vaccines with conventional therapies, the combining of oncolytic viruses with cancer immunotherapy, transplantation, and more. The field of immunotherapy holds great promise that will soon come to fruition if creative investigators can bridge seemingly disparate disciplines, such as T cell therapy, gene therapy, and transplantation therapy. This text is a vital tool in the building of that bridge.
Author: Robert Bazell
Author: Robert Bazell
Author: David Khayat
Author: Connie Henke Yarbro
Author: Melvyn Little
Author: Laurent Degos
Author: Stan B. Kaye`
Author: Kristin Ciriello Pothier
Author: Sara Hurvitz
Author: Jeffrey Medin
Author: